Vietnam pharmacopoeia 4th

DOWNLOAD:

If you don't trust it then don't download ^_^

USP32

GENERAL NOTICES AND REQUIREMENTS

Change to read:

The General Notices and Requirements section (the General Notices) presents the basic assumptions, definitions, and default conditions for the interpretation and application of the United States Pharmacopeia (USP) and the National Formulary (NF).

Requirements stated in these General Notices apply to all articles recognized in the USP and NF (the “compendia”) and to all general chapters unless specifically stated otherwise. Where the requirements of an individual monograph differ from the General Notices or a general chapter, the monograph requirements apply and supersede the requirements of the General Notices or the general chapter, whether or not the monograph explicitly states the difference.

TITLE AND REVISION

The full title of this publication (consisting of three volumes and including its Supplements), is The Pharmacopeia of the United States of America, Thirty-Second Revision and the National Formulary, Twenty-Seventh Edition. These titles may be abbreviated to United States Pharmacopeia, Thirty-Second Revision (or to USP 32), to NF 27, and to USP 32–NF 27. The United States Pharmacopeia, Thirty-Second Revision, and the National Formulary, Twenty-Seventh Edition, supersede all earlier revisions. Where the terms “USP,” “NF,” or “USP–NF” are used without further qualification during the period in which these compendia are official, they refer only to USP 32, NF 27, and any Supplement(s) thereto. The same titles, with no further distinction, apply equally to print or electronic presentation of these contents. Although USP and NF are published under one cover and share these General Notices, they are separate compendia.

This revision is official beginning May 1, 2009, unless otherwise indicated in specific text.

Supplements to USP and NF are published periodically.

Interim Revision Announcements are revisions to USP and NF that are published in Pharmacopeial Forum. Interim Revision Announcements contain official revisions and their effective dates, announcements of the availability of new USP Reference Standards, and announcements of tests or procedures that are held in abeyance pending availability of required USP Reference Standards.

Revision Bulletins are revisions to official text or postponements that require expedited publication. They are published on the USP website and generally are official immediately unless otherwise specified in the Revision Bulletin.

Errata are corrections to items erroneously published that have not received the approval of the Council of Experts and that do not reflect the official requirements. Errata are effective upon publication.

DOWNLOAD:

If you don't trust it then don't download ^_^

British Pharmacopoeia 2009

Published on the recommendation of the Commission on Human Medicines pursuant to the
Medicines Act 1968 and notified in draft to the European Commission in accordance with
Directive 98/34/EEC
The monographs of the Sixth Edition of the European Pharmacopoeia (2007), as amended by
Supplements 6.1 and 6.2 published by the Council of Europe, are reproduced either in this
edition of the British Pharmacopoeia or in the associated edition of the British Pharmacopoeia
(Veterinary).
See General Notices
Effective date: 1 January 2009
see Notices
London: The Stationery Office
In respect of Great Britain:
THE DEPARTMENT OF HEALTH
In respect of Northern Ireland:
THE DEPARTMENT OF HEALTH, SOCIAL SERVICES AND PUBLIC SAFETY
© Crown Copyright 2008
Published by The Stationery Office on behalf of the Medicines and Healthcare products
Regulatory Agency (MHRA) except that:
European Pharmacopoeia monographs are reproduced with the permission of the Council of
Europe and are not Crown Copyright. These are identified in the publication by a chaplet of
stars.
This publication is a 'value added' product. If you wish to re-use the Crown Copyright material
from this publication, applications must be made in writing, clearly stating the material
requested for re-use, and the purpose for which it is required. Applications should be sent to:
Dr M G Lee, MHRA, Market Towers, 1 Nine Elms Lane, London SW8 5NQ or by e-mailing:
ged.lee@mhra.gsi.gov.uk.
First Published 2008
ISBN 978 0 11 322799 0
British Pharmacopoeia Commission Office:
Market Towers
1 Nine Elms Lane
London SW8 5NQ
Telephone: +44 (0)20 7084 2561

DOWNLOAD: 

If you don't trust it then don't download ^_^

Color Atlas of Pharmacology by Heinz Luellmann et al

Preface to the 3rd edition:

   In many countries, medicine is at present facing urgent political and economic calls for reform. These socioeconomic pressures notwithstanding, pharmacotherapy has always been an integral part of the health care system and will remain so in the future. Well-founded knowledge of the preventive and therapeutic value of drugs is a sine qua non for the successful treatment of patients entrusting themselves to a physician or pharmacist.

   Because of the plethora of proprietary medicines and the continuous influx of new pharmaceuticals, the drug market is dif cult to survey and hard to understand. This is true not only for the student in search of a logical systemfor dealing with the wealth of available drugs, but also for the practicing clinician in immediate need of independent information.

   Clearly, a pocket atlas can provide only a basic framework. Comprehensive knowledgehas to be gained frommajor textbooks. As is evident from the drug lists included in the Appendix, some 600 drugs are covered in the present Atlas. This number should be suficient for everyday medical practice and could be interpreted as a Model List. The advances in pharmacotherapy made in recent years have required us to incorporate new plates and text passages, and to expunge obsolete approaches. Several plates needed to be brought in line with new knowledge. As the new edition was nearing completion, several high-profile drugs experiencedwithdrawal from the market, substantive change in labeling, or class action litigation against their manufacturers. Amid growing concern over effectiveness of drug safety regulations, “pharmacovigilance” has become a new priority. It is hoped that this compendium may aid in promoting the critical awareness and rational attitude required to meet that demand.

   We are grateful for comments and suggestions from colleagues, and from students, both doctoral and undergraduate. Thanks are due to Professor R. Lüllmann-Rauch for histological and cell-biological advice. We are indebted to Ms. M. Mauch and Ms. K. Jürgens, Thieme Verlag, for their care and assistance and to Ms. Gabriele Kuhn for harmonious editorial guidance.

Heinz Lüllmann, Kiel

Klaus Mohr, Bonn

Lutz Hein, Freiburg

Detlef Bieger, St. John’s, Canada

Jürgen Wirth, Darmstadt

   Disclosure: The authors of the Color Atlas of Pharmacology have no financial interests or other relationships that would influence the content of this book.

DOWNLOAD: 

        

If you don't trusrt it then don't download ^_^

    

BNF for Children 2014-2015

Preface: BNF for Children aims to provide prescribers, pharmacists, and other healthcare professionals with sound upto- date information on the use of medicines for treating children. A joint publication of the British Medical Association, the Royal Pharmaceutical Society, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group, BNF for Children (‘BNFC’) is published under the authority of a Paediatric Formulary Committee which comprises representatives of these bodies, the Department of Health for England, and the Medicines and Healthcare products Regulatory Agency. Many areas of paediatric practice have suffered from inadequate information on effective medicines. BNFC addresses this significant knowledge gap by providing practical information on the use of medicines in children of all ages from birth to adolescence. Information in BNFC has been validated against emerging evidence, best-practice guidelines, and crucially, advice from a network of clinical experts. Drawing information from manufacturers’ literature where appropriate, BNFC also includes a great deal of advice that goes beyond marketing authorisations (product licences). This is necessary because licensed indications frequently do not cover the clinical needs of children; in some cases, products for use in children need to be specially manufactured or imported. Careful consideration has been given to establishing the clinical need for unlicensed interventions with respect to the evidence and experience of their safety and efficacy; local paediatric formularies, clinical literature and national information resources have been invaluable in this process. BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing, dispensing and administration of medicines. Less detail is given on areas such as malignant disease and the very specialist use of medicines generally undertaken in tertiary centres. BNFC should be interpreted in the light of professional knowledge and it should be supplemented as necessary by specialised publications. Information is also available from Medicines Information Services (see inside front cover). It is important to use the most recent BNFC information for making clinical decisions. The print edition of BNF for Children is updated in July each year. Monthly updates are provided online via the BNF Publications website bnf.org, MedicinesComplete, and the NHS Evidence portal. The more important changes for this edition are listed on p. xvii; changes listed online are cumulative (from one print edition to the next), and can be printed off each month to show the main changes since the last print edition as an aide memoire for those using print copies. The website (bnf.org) includes additional information of relevance to healthcare professionals. Other digital formats of BNFC—including versions for mobile devices and integration into local formularies—are also available.

DOWNLOAD

If you don't trust it then don't download ^_^

Meyler's Side Effects of Drugs (Fifteenth Edition)

The International Encyclopedia of Adverse Drug Reactions and Interactions

Editor: JK Aronson, MA, DPhil, MBChB, FRCP, FBPharmacol S Oxford, United Kingdom

Honorary Editor: 

MNG Dukes, MA, DPhil, MB, FRCP 

Oslo, Norway

Preface: This is a completely new edition of what has become the standard reference text in the field of adverse drug reactions and interactions since Leopold Meyler published his first review of the subject 55 years ago. Although we have retained the old title, Meyler’s Side Effects of Drugs, the subtitle of this edition, The Encyclopedia of Adverse Drug Reactions and Interactions, reflects both modern terminology and the scope of the review. The structure of the book may have changed, but the Encyclopedia remains the most comprehensive reference source on adverse drug reactions and interactions and a major source of informed discussion about them.

Structure: The first major change that readers will notice is that the chapter structure of previous editions has given way to a monographic structure. That is because some of the information about individual drugs has previously been scattered over different chapters in the book; for example ciclosporin was previously covered in Chapter 37 and in scattered sections throughout Chapter 45; it is now dealt with in a single monograph. The monographs are arranged in alphabetical order, with cross-referencing as required. For example, if you turn to the monograph on cetirizine, you will be referred to the complementary general monograph on antihistamines, where much information that is relevant to cetirizine is given; the monograph on cetirizine itself contains information that is

relevant only to cetirizine and not to other antihistamines. Within each monograph the material is arranged in the same way as in the Side Effects of Drugs Annuals (see ''How to use this book’’).

DOWNLOAD: 

If you don't trust it then don't download ^_^

Pharmacotherary 9th: A Pathophysiologic Approach

Author: Joseph T. DiPiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey

eChapters
o eChapter 1. Health Literacy and Medication Use
o eChapter 2. Cultural Competency
o eChapter 3. Principles and Practices of Medication Safety
o eChapter 4. Evidence-Based Medicine
o eChapter 5. Clinical Pharmacokinetics and Pharmacodynamics
o eChapter 6. Pharmacogenetics
o eChapter 7. Pediatrics
o eChapter 8. Geriatrics
o eChapter 9. Palliative Care
o eChapter 10. Clinical Toxicology
o eChapter 11. Emergency Preparedness and Response: Biologic Exposures
o eChapter 12. Emergency Preparedness: Identification and Management of Chemical and Radiologic
Exposures
o eChapter 13. Cardiovascular Testing
o eChapter 14. Introduction to Pulmonary Function Testing
o eChapter 15. Drug-Induced Pulmonary Diseases
o eChapter 16. Evaluation of the Gastrointestinal Tract
o eChapter 17. Drug-Induced Liver Disease
o eChapter 18. Evaluation of Kidney Function
o eChapter 19. Evaluation of Neurologic Illness
o eChapter 20. Evaluation of Psychiatric Disorders
o eChapter 21. Function and Evaluation of the Immune System
o eChapter 22. Allergic and Pseudoallergic Drug Reactions
o eChapter 23. Dermatologic Drug Reactions and Common Skin Conditions
o eChapter 24. Drug-Induced Hematologic Disorders
o eChapter 25. Laboratory Tests to Direct Antimicrobial Pharmacotherapy

Section 1. Cardiovascular Disorders
o Chapter 1. Cardiovascular Testing
o Chapter 2. Cardiac Arrest
o Chapter 3. Hypertension
o Chapter 4. Chronic Heart Failure
o Chapter 5. Acute Decompensated Heart Failure
o Chapter 6. Ischemic Heart Disease
o Chapter 7. Acute Coronary Syndromes
o Chapter 8. The Arrhythmias
o Chapter 9. Venous Thromboembolism
o Chapter 10. Stroke
o Chapter 11. Hyperlipidemia
o Chapter 12. Peripheral Arterial Disease
o Chapter 13. Use of Vasopressors and Inotropes in the Pharmacotherapy of Shock
o Chapter 14. Hypovolemic Shock

Section 2. Respiratory Disorders
o Chapter 15. Asthma
o Chapter 16. Chronic Obstructive Pulmonary Disease
o Chapter 17. Pulmonary Arterial Hypertension
o Chapter 18. Cystic Fibrosis

Section 3. Gastrointestinal Disorders
o Chapter 19. Gastroesophageal Reflux Disease
o Chapter 20. Peptic Ulcer Disease
o Chapter 21. Inflammatory Bowel Disease
o Chapter 22. Nausea and Vomiting
o Chapter 23. Diarrhea, Constipation, and Irritable Bowel Syndrome
o Chapter 24. Portal Hypertension and Cirrhosis
o Chapter 25. Pancreatitis
o Chapter 26. Viral Hepatitis
o Chapter 27. Celiac Disease

Section 4. Renal Disorders
o Chapter 28. Acute Kidney Injury
o Chapter 29. Chronic Kidney Disease
o Chapter 30. Hemodialysis and Peritoneal Dialysis
o Chapter 31. Drug-Induced Kidney Disease
o Chapter 32. Glomerulonephritis
o Chapter 33. Drug Therapy Individualization for Patients with Chronic Kidney Disease
o Chapter 34. Disorders of Sodium and Water Homeostasis
o Chapter 35. Disorders of Calcium and Phosphorus Homeostasis
o Chapter 36. Disorders of Potassium and Magnesium Homeostasis
o Chapter 37. Acid–Base Disorders

Section 5. Neurologic Disorders
o Chapter 38. Alzheimer's Disease
o Chapter 39. Multiple Sclerosis
o Chapter 40. Epilepsy
o Chapter 41. Status Epilepticus
o Chapter 42. Acute Management of the Brain Injury Patient
o Chapter 43. Parkinson's Disease
o Chapter 44. Pain Management
o Chapter 45. Headache Disorders

Section 6. Psychiatric Disorders
o Chapter 46. Attention Deficit/Hyperactivity Disorder
o Chapter 47. Eating Disorders
o Chapter 48. Substance-Related Disorders I: Overview and Depressants, Stimulants, and
Hallucinogens
o Chapter 49. Substance-Related Disorders II: Alcohol, Nicotine, and Caffeine
o Chapter 50. Schizophrenia
o Chapter 51. Major Depressive Disorder
o Chapter 52. Bipolar Disorder
o Chapter 53. Anxiety Disorders I: Generalized Anxiety, Panic, and Social Anxiety Disorders
o Chapter 54. Anxiety Disorders II: Posttraumatic Stress Disorder and Obsessive-Compulsive Disorder
o Chapter 55. Sleep Disorders
o Chapter 56. Disorders Associated with Intellectual Disabilities

Section 7. Endocrinologic Disorders
o Chapter 57. Diabetes Mellitus
o Chapter 58. Thyroid Disorders
o Chapter 59. Adrenal Gland Disorders
o Chapter 60. Pituitary Gland Disorders

Section 8. Gynecologic and Obstetric Disorders
o Chapter 61. Pregnancy and Lactation: Therapeutic Considerations
o Chapter 62. Contraception
o Chapter 63. Menstruation-Related Disorders
o Chapter 64. Endometriosis
o Chapter 65. Hormone Therapy in Women

Section 9. Urologic Disorders
o Chapter 66. Erectile Dysfunction
o Chapter 67. Benign Prostatic Hyperplasia
o Chapter 68. Urinary Incontinence

Section 10. Immunologic Disorders
o Chapter 69. Systemic Lupus Erythematosus
o Chapter 70. Solid-Organ Transplantation

Section 11. Rheumatologic Disorders
o Chapter 71. Osteoarthritis
o Chapter 72. Rheumatoid Arthritis
o Chapter 73. Osteoporosis and Other Metabolic Bone Diseases
o Chapter 74. Gout and Hyperuricemia

Section 12. Ophthalmic and Otolaryngological Disorders
o Chapter 75. Glaucoma
o Chapter 76. Allergic Rhinitis

Section 13. Dermatologic Disorders
o Chapter 77. Acne Vulgaris
o Chapter 78. Psoriasis
o Chapter 79. Atopic Dermatitis

Section 14. Hematologic Disorders
o Chapter 80. Anemias
o Chapter 81. Coagulation Disorders
o Chapter 82. Sickle Cell Disease

Section 15. Infectious Diseases
o Chapter 83. Antimicrobial Regimen Selection
o Chapter 84. Central Nervous System Infections
o Chapter 85. Lower Respiratory Tract Infections
o Chapter 86. Upper Respiratory Tract Infections
o Chapter 87. Influenza
o Chapter 88. Skin and Soft-Tissue Infections
o Chapter 89. Infective Endocarditis
o Chapter 90. Tuberculosis
o Chapter 91. Gastrointestinal Infections and Enterotoxigenic Poisonings
o Chapter 92. Intraabdominal Infections
o Chapter 93. Parasitic Diseases
o Chapter 94. Urinary Tract Infections and Prostatitis
o Chapter 95. Sexually Transmitted Diseases
o Chapter 96. Bone and Joint Infections
o Chapter 97. Severe Sepsis and Septic Shock
o Chapter 98. Superficial Fungal Infections
o Chapter 99. Invasive Fungal Infections
o Chapter 100. Infections in Immunocompromised Patients
o Chapter 101. Antimicrobial Prophylaxis in Surgery
o Chapter 102. Vaccines, Toxoids, and Other Immunobiologics
o Chapter 103. Human Immunodeficiency Virus Infection

Section 16. Oncologic Disorders
o Chapter 104. Cancer Treatment and Chemotherapy
o Chapter 105. Breast Cancer
o Chapter 106. Lung Cancer
o Chapter 107. Colorectal Cancer
o Chapter 108. Prostate Cancer
o Chapter 109. Lymphomas
o Chapter 110. Ovarian Cancer
o Chapter 111. Acute Leukemias
o Chapter 112. Chronic Leukemias
o Chapter 113. Multiple Myeloma
o Chapter 114. Myelodysplastic Syndromes
o Chapter 115. Renal Cell Carcinoma
o Chapter 116. Melanoma
o Chapter 117. Hematopoietic Stem Cell Transplantation

Section 17. Nutritional Disorders
o Chapter 118. Assessment of Nutrition Status and Nutrition Requirements
o Chapter 119. Parenteral Nutrition
o Chapter 120. Enteral Nutrition

o Chapter 121. Obesity

DOWNLOAD: 

If you don't trust it then don't download ^_^